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NR4AThe NR4A subfamily of nuclear receptors consists of three mammalian members: Nur77, Nurr1, and NOR-1. The
NR4A receptors are involved in essential physiological processes such as adaptive and innate immune cell differ-
entiation, metabolism and brain function. They act as transcription factors that directly modulate gene expres-
sion, but can also form trans-repressive complexes with other transcription factors. In contrast to steroid
hormone nuclear receptors such as the estrogen receptor or the glucocorticoid receptor, no ligands have been
described for the NR4A receptors. This lack of known ligands might be explained by the structure of the
ligand-binding domain of NR4A receptors, which shows an active conformation and a ligand-binding pocket
that is ﬁlled with bulky amino acid side-chains. Other mechanisms, such as transcriptional control, post-
translational modiﬁcations and protein–protein interactions therefore seem to be more important in regulating
the activity of theNR4A receptors. For Nur77, over 80 interacting proteins (the interactome) have been identiﬁed
so far, and roughly half of these interactions has been studied in more detail. Although the NR4As show some
overlap in interacting proteins, less information is available on the interactome of Nurr1 and NOR-1. Therefore,
the present reviewwill describe the current knowledge on the interactomes of all three NR4A nuclear receptors
with emphasis on Nur77.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The nuclear receptor family of 48 proteins comprises steroid hormone
receptors, nuclear receptors that heterodimerize with retinoid X recep-
tors (RXRs), and a number of so called orphan receptors. A typical nuclear
receptor contains a central double zinc ﬁnger DNA-binding domain
(DBD), a carboxyl-terminal ligand-binding domain (LBD) composed of
12 α-helices, and an unstructured amino-terminal domain (N-term)
(Fig. 1) [1]. The ligands of nuclear receptors are usually small, non-
protein compounds such as steroid hormones, retinoids, fatty acids or
cholesterol derivatives. In this review we describe the NR4A-subfamilyis-retinoic acid; AMP, adenosine
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.of orphan receptors comprised of Nur77 (also known as NR4A1, TR3,
NGFI-B), Nurr1 (NR4A2) and NOR-1 (NR4A3), for which no ligand has
been identiﬁed yet. The amino acid sequences of the different NR4A
DBDs are almost identical, whereas the LBDs show a sequence similarity
of 58–65%. Meanwhile, the N-terminal domains aremost divergent, with
only 26–28% amino acid sequence similarity between the NR4As.This
domain is therefore also the most likely to exhibit diversity in protein–
protein interactions (Fig. 1). NR4A receptors are involved in a plethora
of cellular processes and their activity is mainly regulated through alter-
ations in gene expression, post-translational modiﬁcations and interac-
tions with coregulatory proteins. In this review we put together the
wealth of information that is available on the interactome of theNR4A re-
ceptors with a focus on Nur77, for which most protein–protein interac-
tions have been described. We categorized the Nur77-binding proteins
into three groups: transcription factors, transcriptional coregulators and
kinases. The proteins interacting with Nurr1 and NOR-1 are described
in a separate part of the review. The protein–protein interactions de-
scribed in this review are summarized in Tables 1 through 5, while the
protein–protein interactions of Nur77 that have a known binding site
are also shown schematically in Fig. 2.
2. Interactions between Nur77 and other transcription factors
Nur77 acts as a transcription factor with its two zinc ﬁngers in the
DBD mediating direct binding to DNA. Nur77 binds as a monomeric
factor on theNGFI-B response element (NBRE; AAAGGTCA) or as a homo-
dimer to Nur-response elements (NurREs; TGATATTTn6AAATGCCA) in
DBD LBDN-termNuclear Receptor
94-95% 58-65%26-28%Similarity NR4As
Fig. 1. Schematic representation of the domain structure of nuclear receptors. Nuclear re-
ceptors are composed of an N-terminal domain (N-term), a central DNA-binding domain
(DBD) and a ligand-binding domain (LBD). The amino acid similarity between the individ-
ual domains of Nur77 with Nurr1 and NOR-1 is given in percentages below the domains.
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Nur77 with other transcription factors modulates its transcriptional
activity. Vice versa, such protein–protein interactions can also result in
enhancement or inhibition of the activity of the interacting transcription
factor itself (see Table 1). The following paragraphs will focus on those
interactions between Nur77 and other transcription factors for which
the outcome on transcriptional activity has been determined in a physio-
logical context.2.1. Nur77 in the regulation of endocrine signals and steroid hormone
synthesis
Nur77 is expressed in endocrine tissues and in organs that are crucial
for steroid hormone synthesis such as the adrenal glands, the pituitary
gland and the testes. The ﬁrst functional NurRE was identiﬁed in the
promoter of the pro-opiomelanocortin (POMC) gene of pituitary-
derived AtT-20 cells [2]. Nur77 can bind this NurRE either as a homodi-
mer or as a heterodimerwith either one of the other two NR4A receptors
Nurr1 and NOR-1. Interestingly, it was shown that these heterodimers
enhance POMC gene transcription more potently than homodimers ofTable 1
Transcription factors interacting with Nur77.
Transcription factor Also known as Intera
Coactivators of Nur77
CREB CREB1 N-ter
NOR-1 NR4A3; MINOR
Nur77 NR4A1; TR3; NGFI-B
Nurr1 NR4A2; NOT
RXRγ NR2B3; RXRC; RXRgamma N-ter
Coactivated by Nurt77
c-Jun AP-1; AP1; c-Jun; C-JUN; cJun LBD
RXRα NR2B1; RXR alpha LBD
SP1
SP4
p53 TP53; TRP53 DBD–
Corepressed by Nur77
COUP-TFI NR2F1; EAR3
COUP-TFII NR2F2; COUPTFB
GR NR3C1; GCR; GRL; GCCR DBD
NF-κB (p65) EBP-1; KBF1; NF kappa B; NFκB
p53 TP53; TRP53 DBD–
RXRα NR2B1; RXR alpha LBD
Corepressor of Nur77
AR NR3C4 N-ter
DAX1 NR0B1; DAX-1; DSS LBD
ERα NR3A1; ER; ESR1; Era; ESRA; DBD–
GR NR3C1; GCR; GRL; GCCR DBD
c-JUN AP-1; AP1; c-Jun; C-JUN; cJun LBD
NF-κB (p65) EBP-1; KBF1; NF kappa B; NFκB LBD
Notch-1 hN1; TAN1 DBD–
PML MYL; TRIM19 DBD
RARα NR1B1; RAR
RXRα NR2B1; RXR alpha DBD
SHP NR0B2; SHP-1 N-ter
Other function
ß-catenin CTNNB1; armadillo Nur77
RXRα NR2B1; RXR alpha Trans
VHL pVHL; VHL1 Nur77Nur77 do, suggesting that there is interdependency between the NR4A
receptors in activating their target genes [3].
The NurRE sequence in the POMC promoter also partially overlaps
with a STAT1-3 response element. Philips et al. showed that Nur77
and STAT1-3 bind simultaneously to this so called NurRE-STAT compos-
ite site and synergistically enhance transcription of the POMC gene.
However, Nur77 and STAT1-3 do not interact directly, which suggests
that one or more facilitating factors are involved in NurRE-STAT driven
transcription. Mynard et al. showed that this third factor is cAMP re-
sponse element binding protein (CREB), which binds both STAT1-3
and Nur77 and indirectly enhances transcription of the POMC gene by
facilitating the synergistic activation of the NurRE-STAT composite site
by STAT1-3 and Nur77 [4].
Nur77 also plays an important role in the steroidogenic acute regu-
latory protein (StAR)-mediated testosterone production by Leydig
cells. StAR is required for the transport of cholesterol through the mito-
chondrial membrane to initiate steroid hormone synthesis. Nur77 binds
to an NBRE in the StAR promoter, which is in close proximity to an AP-1
response element. In response to cAMP stimulation c-Jun and Nur77
synergistically increase StAR gene expression [5], presumably through
a direct interaction between c-Jun and the LBD of Nur77 [6]. On the
other hand, c-Jun has also been shown to suppress expression of the hy-
droxylase P450c17 gene by blocking the DNA-binding activity of Nur77
in response to stimulation of Leydig cells with reactive oxygen species
[7]. The effect of c-Jun on the transcriptional activity of Nur77 therefore
seems to depend on other factors as well. One of these factors could be
the atypical nuclear receptor DAX1 (NR0B1), which lacks a DBD and as-
sociateswithmultiple coregulatory proteins. DAX1 bindsNur77directly
and represses its ability to enhance transcription of the previouslymen-
tioned P450c17 gene. This inhibition is mainly the result of competitioncting domain of Nur77 References
m [4]
[3]
[3]
[3]
m; LBD [15]
[7]
[16,17]
[34,35]
[34,35]
LBD [67]
[26]
[26]
[11]
[42]
LBD [38]
[21]
m [12]
[8]
LBD [13]
[9,10]
[6]
[14]
LBD [37]
[36]
[22]
[22]
m [28]
inhibits β-catenin signaling by inducing its degradation [33]
location of hetero-dimers to the cytoplasm [17,20,21,24]
inhibits VHL-associated E3-ligase activity [40]
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coactivator-1 (SRC-1), which is a transcriptional coactivator of Nur77
that will be described in more detail later on in this review [8].
Recruitment of Nur77 to the StAR promoter is inhibited by the
synthetic glucocorticoid receptor (GR) ligand dexamethasone [5].
GR and Nur77 interact directly through their DBDs and subsequent
transrepression of Nur77 involves the formation of a transcriptionally
inactive complex comprised of GR, Brg1, Brm and HDAC2 on the
POMC promoter [9–11]. Interestingly, dexamethasone stimulation in-
creases DAX1 expression levels, suggesting that DAX1 also plays a role
in GR-mediated transrepression of Nur77 [11]. Additionally, Nur77
was shown to reciprocally inhibit the activity of GR in CV-1 cells, pre-
sumably through the formation of the previously mentioned transcrip-
tionally inactive complexes [11].
Steroid hormone synthesis is tightly regulated, and both the andro-
gens and 17-β-estradiol (E2) activate negative feedback loops involving
Nur77. Upon ligand binding, the androgen receptor (AR) can inhibit
Nur77 activity through interaction of the N-terminal domain of Nur77
with the DBD of AR. Competition for SRC-1 binding was identiﬁed as
the underlying mechanism for this inhibition of Nur77 activity, analo-
gous to DAX1 inhibition [12]. The estrogen receptor alpha (ERα) binds
with its DBD-hinge region the DBD–LBD domains of Nur77, thereby
blocking Nur77 DNA-binding and thus activity [13]. Finally, TNFα was
shown to inhibit the expression of steroidogenic enzymes through
induction of NF-κB and subsequent inhibition of Nur77 transcriptional
activity [14]. The interaction between Nur77 and NF-κBwill be described
in more detail below.
2.2. Interaction between Nur77, RXRs and RARs modulates apoptosis
The three retinoidX receptors (RXRα,β andγ) can formheterodimers
with multiple nuclear receptors and bind 9-cis-retinoic acid (9-cis-RA) in
their ligand-binding pocket. RXRs are silenced when dimerized with the
retinoic acid receptors (RARs). In contrast, both Nur77 and Nurr1, but
not NOR-1, can form activating heterodimerswith RXRs on DR5 response
elements (GGTTCAn5AGTTCA). So far, Nur77 has been shown to interact
with both RXRα and RXRγ. RXRγwas found to enhance Nur77 transcrip-
tional activity, which was further increased upon addition of the RXR
ligand 9-cis-RA. This interaction can therefore make Nur77 indirectly re-
sponsive to retinoic acids [15]. Similarly, Nur77 can form heterodimers
with RXRα that are also activated by 9-cis-RA with Nur77 acting as an
activator of RXRα-dependent transcription [16]. In the absence of RXRα
activating ligands, Nur77 and RXRα heterodimerize via their DBDs.
Ligand binding by RXRα induces a conformational change, which alters
the dimerization interface and allows for dimerization of Nurr77 and
RXRα through their LBDs. This interactionmasks the leucine-rich nuclear
export signal (NES) of RXRα, thereby preventing nuclear export and in-
creasing transcription of RA-response genes [17]. 9-cis-RA was also
shown to arrest Nur77-RXRα heterodimers in the nucleus of neuronal
cells, thereby protecting these cells from glutamate-induced apoptosis
[18] and in pluripotent embryonic stem cells [19]. In contrast to the
above ﬁndings, 9-cis-RA was shown to induce rather than inhibit nuclear
export and mitochondrial localization of Nur77-RXRα dimers in gastric
cancer cells [20,21]. Futhermore, Nur77 was shown to decrease RXRα
transcriptional activity by competing with the coactivator CBP/p300 for
RXRα binding in these cells [21]. Finally, in Jurkat cells RA-dependent re-
pression of Nur77 activity by both RAR and RXR has been described [22].
Together these data illustrate that the outcome of Nur77-RXR interaction
is highly dependent on the cell type, the stimulus and the presence of
retinoic acids. Furthermore, retinoic acids are unstable and are metabo-
lized in different ways in distinct cell types so one may speculate that a
speciﬁc metabolite of 9-cis-RA is responsible for nuclear export and regu-
lation of activity of Nur77-RXRα dimers. This hypothesis remains to be
tested however [23].
Other stimuli also play a role in modulating the interaction between
Nur77 and RXRα: in response to either apoptotic stimuli or nervegrowth factor (NGF) treatment, Nur77 translocates from the nucleus
to the cytoplasm as part of a Nur77-RXRα heterodimer. Although
these two stimuli have similar downstream effects (nuclear export of
Nur77-RXRα), the exact mechanism through which they achieve this
effect seems to be either fundamentally different or very dependent
on cell type [17,24]. In PC12 cells NGF-induced translocation requires
the presence of a NES in the LBDof Nur77 thereby regulating the subcel-
lular distribution of RXRα [24]. On the other hand, RXRα is required for
shuttling of Nur77 from the nucleus to the cytoplasm in response to ap-
optotic stimuli in prostate cancer cells, as the export of Nur77-RXRα
heterodimers in these cells is dependent on a NES present in the LBD
of RXRα [17]. It could be hypothesized that cell-type speciﬁc tertiary
proteins that modulate the interactions between Nur77 and RXRα de-
scribed above cause these differences in the nuclear export mechanism.
For example, in smooth muscle cells, interferon stimulated gene 12
(ISG12) interacts with and inhibits the transcriptional activity of
Nur77 by facilitating Crm1-dependent nuclear export of Nur77 [25].
After nuclear export, Nur77-RXRα heterodimers are targeted to themi-
tochondria where Nur77 induces apoptosis via interaction with Bcl-2, a
process that will be described in more detail further on in this review.
Related to the interactions betweenNur77 and the RXRs are COUP-TFI
and COUP-TFII. These nuclear receptors bind and repress RARs through
competition for DNA binding. Interactions between Nur77 and COUP-
TFI/II may therefore result in enhanced expression of RAR-responsive
genes. At the same time, binding of the COUP-TFs to Nur77 also inhibits
Nur77-RXRheterodimer formation, thereby inhibiting the transcriptional
activity of these complexes [26]. In short, COUP-TFs add an additional
layer of regulation to the interactions between Nur77 and the RXRs.
2.3. Interaction of Nur77with other transcription factors in cell proliferation
and apoptosis
Nur77 has been implicated in the regulation of cellular survival,
proliferation and apoptosis in different tissues and cell types involving
various mechanisms, as reviewed by Moll et al. [27]. In this section we
focus on the interaction of Nur77 with transcription factors that are ac-
tively involved in these processes.
In cultured hepatocytes the atypical nuclear receptor SHP interacts
with a variety of nuclear receptors, including Nur77. The SHP protein
only consists of a putative LBD and binds either Nur77 or the coactivator
CBP/p300. Through this binding it can sequester this activator away
from Nur77 resulting in inhibition of Nur77 activity [28]. In addition to
this direct interaction, Yeo et al. also described SHP as a modulator of
Nur77-mediated apoptosis in hepatocytes. The exact role of Nur77 in
hepatocyte apoptosis is still unclear however, as adenovirus-mediated
overexpression of Nur77 in mouse liver does not result in extensive apo-
ptosis in this organ [29,30].
β-catenin is a dual function protein: it can either regulate cell–cell
adhesion as a transmembrane protein or alter gene expression as a tran-
scription factor after proteolytic release from the membrane. Notably,
Nur77 gene expression is indirectly increased through activation of
the AP-1 transcription factor complex by β-catenin [31]. In addition to
regulation of Nur77 gene expression, β-catenin and Nur77 also interact
directly and this interaction plays an important role in ubiquitin-
mediated proteasomal degradation of β-catenin. More speciﬁcally,
Nur77 binds β-catenin through its LBD and subsequently becomes
ubiquitinated on its N-terminal domain. The proteasome subsequently
degrades this entire complex of ubiquitinated Nur77 and β-catenin. In-
hibition of nuclear export of Nur77 through mutagenesis of the NES in
the LBD of Nur77 abolishes this degradation-inducing interaction with
β-catenin. Additionally, Nur77 mutants lacking a DBD and associated
nuclear localization signals (NLS) show increased binding and degrada-
tion of β-catenin. These two observations strongly suggest that this in-
teraction takes place exclusively in the cytoplasm [31–33].
In pancreatic cancer cells, Nur77 was shown to bind Sp1 and Sp4
transcription factors, which are recruited to GC-rich sites in the promoter
2546 K. Kurakula et al. / Biochimica et Biophysica Acta 1843 (2014) 2543–2555of the cyclin-dependent kinase inhibitor p21. The effect on the survival
and growth of these cells remains unclear although the enhanced p21
expression would potentially inhibit cell proliferation [34]. However, in
another study of the same pancreatic cancer cells it was demonstrated
that the Nur77/Sp1-complex induces expression of Survivin, a member
of the inhibitors of the apoptosis family, resulting in cell survival and pro-
liferation [35].
The promyelocytic leukemia protein (PML) is a tumor suppressor
involved in apoptosis and regulation of cell cycle progression. PML in-
teracts with the DBD of Nur77 via its coiled-coil domain thereby
inhibiting Nur77 binding to DNA [36]. In the human osteosarcoma
U2OS cell line Nur77-dependent apoptosis is enhanced by PML. Finally,
the intracellular region of the transmembrane protein Notch-1 is re-
leased upon proteolytic cleavage and translocates to the nucleus
where it can bind Nur77 and inhibit Nur77-dependent cell death of
T-cells [37].
Taken together, these data illustrate that Nur77 interacts with a
plethora of transcription factors that are active in cellular survival,
growth and apoptosis and that the ﬁnal outcome of these interactions
on both Nur77 activity and cellular behavior is variable. One should re-
alize that not all proteins mentioned are expressed to the same extent
and under the same conditions in the different cell systems, which
most likely explains the diverse outcome on Nur77 function.
2.4. Nur77modulates tumor progression and angiogenesis through interac-
tions with p53 and HIF-1α
The anti-cancer function of the tumor suppressor p53 involves cell
cycle arrest, maintenance of genomic stability, apoptosis and inhibition
of angiogenesis. Acetylation of p53 is blocked upon complex formation
between p53 and Nur77, which suppresses the transcriptional activity
of p53 [38]. The p53 target gene mouse double minute 2 (MDM2) is
an E3 ligase that binds and ubiquitinates p53, but not Nur77. Nur77
can bind to p53 with a higher afﬁnity than MDM2 and through this
competition for binding Nur77 inhibits MDM2-mediated ubiquitination
and degradation of p53. As a consequence, self-ubiquitination and sub-
sequent degradation of MDM2 is promoted [38]. Taken together, the in-
teraction of Nur77 with p53 downregulates both MDM2 mRNA
(through a decrease in p53 transcriptional activity) and protein levels
(through an increase in self-ubiquitination). Nur77 also stabilizes hyp-
oxia inducible factor (HIF)-1α in a similar fashion: HIF-1α protein isTable 2
Transcriptional coregulators interacting with Nur77.
Name Also known as
ARR19 CKLFSF2; CMTM2
AXIN2 AXIL
BCL2 Bcl-2; PPP1R50
BRG1 SMARCA4; BAF190; SNF2; SWI2; hSNF2b
BRM SMARCA2; BAF190; NCBRS; SNF2; SNF2L2; SWI2; Sth1p; hSNF2a
CBP/p300 CBP; CREBBP; KAT3A; RSTS; p300; EP300; KAT3B
CRIF1 CKBBP2; GADD45GIP1
FHL2 DRAL; SLIM3
HDAC1 GON-10; HD1; RPD3; RPD3L1
ISG12 IFI27; ISG12A; P27
PCAF KAT2B
PIN1 DOD; UBL5
PRMT1 HRMT1L2; IR1B4
RB1 p105-Rb; pp110; pRb
SMAD7 CRCS3; MADH7; MADH8
SMRT NCOR2; SMAP270; SMRTE; TRAC1
SRC-1 NCOA1; F-SRC-1; RIP160
SRC-2 NCOA2; GRIP1; NCoA-2; TIF2
TIM-1 HAVCR1; KIM-1
TIM-3 HAVCR2; KIM-3
TIM-4 SMUCKLER
TIF1β TRIM28; KAP1; TIF1B
TRAP220 MED1; CRSP1; DRIP205; PBP; PPARBP; RB18A; TRIP2
N-term, indicates N-terminal domain;−, binding partner represses Nur77 activity; +, activaticontinuously degraded due to interaction with MDM2, but is stabilized
under hypoxic conditions to induce the expression of genes crucial in
angiogenesis. Nur77 expression is also increased in response to hypoxia,
leading to reduced MDM2 expression, decreased ubiquitination and
degradation of HIF-1α and enhanced expression of HIF-1α target
genes [39]. An additional mechanism bywhich Nur77 inhibits degrada-
tion of HIF-1α involves interaction with the von Hippel–Lindau protein
(pVHL). In the presence of oxygen pVHL forms a complex that exhibits
E3 ubiquitin ligase activity, leading to HIF-1α ubiquitination and
subsequent degradation. Under hypoxic conditions Nur77 binds to
the α-domain of pVHL, thereby blocking pVHL-mediated HIF-1α
ubiquitination and thus degradation [40].
2.5. Nur77 modulates inﬂammatory responses through interaction with
NF-κB
In mice, Nur77 is involved in negative selection of thymocytes, reg-
ulatory T cell differentiation, development of Ly6C-low monocytes and
attenuation of the chronic inﬂammatory response of macrophages in
atherosclerosis [1,41]. In Jurkat cells the anti-inﬂammatory function of
Nur77 is mediated at least partly through its direct interaction with
the p65 (RelA) subunit of NF-κB [14]. The NF-κB binding sites in
IL2- and IL8-promoters have been shown to preferentially bind
p65- or c-Rel homodimers or p65-c-Rel heterodimers. Nur77 respresses
the transcriptional activity of p65 and c-Rel on these low afﬁnity binding
sites, but not on the high afﬁnity NF-κB response element derived from
the HIV-LTR. Reciprocally, p65 was shown to inhibit the transcriptional
activity of Nur77 on NurREs [42].
3. Interactions between Nur77 and transcriptional coregulatory
proteins
Target gene transcription by Nur77 is modulated through interac-
tion with coregulatory factors that either enhance or repress interac-
tions between Nur77 and the transcriptional machinery [43]. Both the
N-terminal domain and LBD of Nur77 play a crucial role in transcrip-
tional activation, coregulator recruitment and intra- and intermolecular
interactions [15]. Some coregulators of Nur77 display speciﬁcity for
either the NBRE or the NurRE promoter element and most coregulators
have been characterized in a cell type- and stimulus-speciﬁc manner
(Table 2). Coregulators of Nur77 have diverse enzyme functionsEffect on Nur77 activity Interacting domain of Nur77 References
− LBD [51]
[54]
LBD [56,57]
− [9]
− [9]
+ N-term; LBD [15,28,46,47]
− N-term [50]
− N-term; DBD [59]
− LBD [46]
− [25]
+ N-term [15]
+ N-term; DBD [63,64]
+ DBD–LBD [49]
+ DBD [45]
[54]
− LBD [43,52]
+ N-term; LBD [15,43,44]
+ N-term [15]
− LBD [60]
− LBD [60]
− LBD [60]
+ N-term [48]
N-term [105]
on of Nur77 transcriptional activity.
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(HDAC), methyltransferase and isomerase activities.
3.1. Interactions with steroid receptor coactivators (SRCs) increase the
transcriptional activity of Nur77 and are extensively modulated by other
protein–protein interactions
Muscat et al. generated a model for the structure of the LBD of
Nur77 and predicted that the coregulator-binding groove that is
formed in the LBDs of most nuclear receptors upon ligand binding
is absent in Nur77 [15]. The lack of this binding groove, which can in-
teract with LxxLL motifs of coregulatory proteins, may explain why
most coregulators interact with the N-terminal domain of Nur77
instead.
The steroid receptor coactivators (SRCs)1-3 are three members of
the p160 family of histone acetyl transferases (HATs) that are critical
for transactivation of many nuclear receptors. Both SRC-1 and SRC-2
can directly interact with the N-terminal domain of Nur77 and enhance
its transcriptional activity. Interestingly, SRC-1 can also interactwith the
LBD of Nur77 even though this domain does not contain the previously
mentioned coregulator-binding groove [15]. Additionally, SRC-1 only
increases the transcriptional activity of Nur77 on NurREs (which are
bound by NR4A dimers) but not NBREs (which are bound by NR4A
monomers) [15,44]. The latter two facts suggest a possible role for
SRC-1 in facilitating NR4A dimerization through interaction with the
LBD of Nur77. At present, both the role of SRC-1 in NR4A dimerization
and the importance of the innate acetyltransferase activity of SRC-1 or
SRC-2 in the transcriptional activation of Nur77 remain unknown. Fur-
thermore, many other coregulatory proteins have been found to either
increase or decrease the activation of Nur77 by SRC-1 and SRC-2. This
ﬁnding suggests that cells regulate Nur77 activation by SRC-1 and
SRC-2 through protein–protein interactions instead of ligand binding,
which ﬁts with the fact that Nur77 does not contain a classical nuclear re-
ceptor LBD that recruits coregulators like SRC-1 in a ligand-dependent
fashion.
Multiple proteins have been shown to increase transactivation of
Nur77 by SRC-1 or SRC-2. First, retinoblastoma tumor suppressor pro-
tein (Rb) is a repressor of genes involved in cell cycle progression. Rb
and its related proteins p107 and p130 increase the activity of Nur77
through direct interaction with the N-terminal domain and the DBD of
Nur77. Although SRCs can bind Nur77 in the absence of Rb, Rb acts as a
synergistic potentiator of SRC-2 coactivator function, thereby promoting
Nur77 activity [45].
Second, p300/CBP-associated factor (PCAF) is a HAT that binds
directly to the N-terminal domain of Nur77 and mediates recruitment
of additional coactivators. Together with SRC-1, SRC-2 and CBP/p300,
PCAF works with the mediator complex to remodel local chromatin
structure, thereby enhancing transcription [15]. In addition to interac-
tionswith PCAF, Nur77 is also a target for acetylation by CBP/p300 itself.
This acetylation increases protein stability of Nur77 and is directly an-
tagonized by histone deacetylase 1 (HDAC1) [46]. Interestingly, Nur77
induces expression of both the acetylase p300 and the deacetylase
HDAC1, pointing to the existence of a negative feedback loop that regu-
lates Nur77 activity and is itself regulated at the post-transcriptional
level [46,47].
Third, transcription intermediary factor 1β (TIF1β) is an intrinsic
component of two chromatin remodeling and histone deacetylase
complexes: the NCoR1 complex and the nucleosome remodeling and
deacetylation (Mi-2/NuRD) complex. TIF1β increases the transcription-
al activity of Nur77 upon corticotropin-releasing hormone (CRH) stim-
ulation of AtT-20 cells by forming a transcriptional activation complex
together with SRC-2 on the N-terminal domain of Nur77. It should be
noted that TIF1β acts only on Nur77/NR4A dimers but not on mono-
mers. Additionally, TIF1β also interacts with the other two members
of the NR4A family, which will be discussed in a separate section of
this review [48].Finally, protein arginine methyltransferase 1 (PRMT1) physically
interacts with Nur77 and synergizes with SRC-2 to increase Nur77 tran-
scriptional activity. However, Nur77 is not methylated by PRMT1 [49].
Instead, PRMT1 increases the protein stability of Nur77 through direct
interaction independent of its methyltransferase activity. Interestingly,
this interaction also blocks the methyltransferase activity of PRMT1 by
masking its catalytic domain, resulting in decreased methylation of
PRMT1 substrates such as STAT3 and Sam68, indirectly leading to either
a decrease in their transcriptional activity (for STAT3) or a decrease in
their nuclear localization (for Sam68) [49].
On the other hand, two proteins have been shown to decrease the
activation of Nur77 by direct competition with either SRC-1 or SRC-2.
First, CR6-interacting factor 1 (CRIF1), a putative regulator of cell cycle
progression and cell growth, has been shown to interact directly with
the N-terminal domain of Nur77 via its mid-region and decrease
transactivation of Nur77 by SRC-2. In thyroid cells this binding resulted
in a decrease of Nur77-dependent induction of E2F1 promoter activity
and Nur77-mediated G1/S progression of the cell cycle [50].
The second, androgen receptor corepressor-19 (ARR19), is a
member of the chemokine-like factor superfamily and reduces the
expression of steroidogenic enzymes. ARR19 can inhibit the transcrip-
tional activity of Nur77 by directly competing with SRC-1 for binding
of the LBD of Nur77 [51]. As was previously stated, SRC-1 could hypo-
thetically affect dimerization of Nur77. Unfortunately, Qamar et al. did
not look at the effect of ARR19 or SRC-1 on NR4A dimerization in this
study.
Similarly, although not directly related to modulation of SRC-1 and
SRC-2 activity, the silencingmediator for retinoid and thyroid hormones
(SMRT) was shown to bind the LBD of Nur77 and repress its transcrip-
tional activity. SMRT is a known corepressor of multiple nuclear recep-
tors and associates with HDACs to form repressive complexes. The
HDAC inhibitor Trichostatin A (TSA) does not block the repressive effects
of SMRT on Nur77 however, suggesting that HDACs do not play a role in
this process. Instead, Sohn et al. hypothesize that SMRT competes with
other coregulatory proteins (such as the SRCs) for binding of Nur77
[52]. Furthermore, it should be noted that the inhibitory effect of SMRT
on Nur77 is repressed by Ca2+/calmodulin-dependent protein kinase
IV (CaMKIVc), which facilitates the translocation of SMRT from the nu-
cleus to the cytoplasm [52]. Additionally, increases in cytosolic calcium
enhance expression of Nur77 [53], while increases in intracellular
cAMP levels enhance expression of both Nur77 and SMRT [43]. When
taking these three facts together, it could be hypothesized that the effect
of a stimulus that sequentially increases cytosolic Ca2+ and cAMP levels
(such as those relayed by the β-adrenergic receptors) on Nur77 is a two-
stage affair that is regulated by SMRT: ﬁrst, when cytosolic calcium and
cAMP levels are high, expression of both SMRT and Nur77 is increased
while SMRT protein is sequestered in the cytosol by CaMKIVc, leading
to an increase in Nur77 transcriptional activity. Then, when the said
stimulus has passed and cytosolic calcium levels return to normal,
SMRT is no longer exported from the nucleus and starts inhibiting
Nur77, thereby ending the Nur77-dependent response of the cell to
such a stimulus.
Finally, Sohn et al. also describe the coactivator ASC-2 (NCOA6),
which increases the transcriptional activity of Nur77 but does not bind
it directly. The interaction between ASC-2 and Nur77 is said to bemedi-
ated by an intermediary protein that has not been identiﬁed yet [52].
Since it has been shown that ASC-2 interacts with both RXRα and
RARα [54], it could be hypothesized that the previously mentioned di-
merization of Nur77 with these two receptors plays a role in the activa-
tion of Nur77 by ASC-2.
3.2. Nur77 promotes thymocyte apoptosis through interaction with Bcl-2
Nur77 has been shown to induce cell death through a transcription-
dependent pathway in thymocytes [55], while Bcl-2 family proteins are
evolutionarily conserved regulators of apoptosis [56]. Upon apoptotic
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chondria, a process which is tightly controlled by post-translational
modiﬁcations such as phosphorylation (more on this later). When
Nur77 binds to Bcl-2 in mitochondria cytochrome C is released into
the cytosol, which subsequently triggers apoptosis. The interaction of
Nur77with Bcl-2 induces a conformational change resulting in the con-
version of Bcl-2 from an anti-apoptotic to a pro-apoptotic protein [56].
The translocation of Nur77 from the nucleus to the mitochondria is
also observed in cancer cells derived from lung, ovary, prostate, stomach
and breast [27]. Nur77 and NOR-1 associate with the proapoptotic BH3
domain of Bcl-2 in stimulated thymocytes, whichwas conﬁrmed in cells
from T-cell receptor-transgenic mouse models [57]. Recently, Kolluri
et al. developed a short Nur77-derived peptide, NuBCP-9, which poten-
tiates the pro-apoptotic function of Bcl-2 to induce apoptosis of cancer
cells in vitro and in animal models [58].
3.3. Regulation of Nur77 transcriptional activity by FHL2, TIMs and TGFβ
signaling
Four and a half LIMdomain protein-2 (FHL2) is a typical adaptor pro-
tein that facilitates interactions between different proteins and interacts
directly with all three NR4As [59]. All four LIM domains of FHL2 can
bind Nur77 and both the N-terminal domain and the DBD of Nur77 are
involved in this interaction. FHL2 inhibits Nur77 transcriptional activity,
presumably through recruitment of additional, repressive coregulators
of Nur77 [59].
T-cell immunoglobulin and mucin domain (TIM) proteins such as
TIM-1, TIM-3 and TIM-4 function as cell-surface signaling receptors in
T-cells and scavenger receptors in antigen-presenting cells. All three
TIM proteins interact with Nur77 and repress its transcriptional
activity [60]. It was also shown that TIM-1 is constitutively endocytosed
and that this dynamic cycling of TIM-1 is important for simultaneously
targeting Nur77 to the lysosome for degradation. As such, the association
of TIM-1withNur77 in renal tubular epithelial cellsmay confer protection
against apoptosis [60].
More recently, itwas shown thatNur77 strongly potentiates oncogen-
ic TGFβ signaling in breast tumor cells by interactingwith both Axin2 and
Smad7. These interactions lead to increased Axin2-dependent degrada-
tion of Smad7, a negative regulator of TGFβ signaling [61]. So far it is un-
known whether or not these interactions also have a reciprocal effect on
the activity of Nur77, although it has been shown that Axin2, like Nur77,
enhances degradation of β-catenin, suggesting that Axin2 plays a role in
this Nur77-mediated degradation process as well [62].
4. Interactions with kinases and phosphorylation of Nur77
Phosphorylation is a post-translational proteinmodiﬁcation that can
change the conformation of an entire protein or, alternatively, alter theTable 3
Kinases that interact directly with Nur77.
Kinase Also known as Effect of phosphorylation
AKT1 AKT; PKB Decreases transcriptional activity, blocks nuclear export o
CHEK2 CDS1; CHK2; RAD53 Increases DNA-binding ability of Nur77
CK2 CSNK2A1/A2/B; CKII Mediates stabilization of Nur77 by Pin1
DNA-PK PRKDC Promotes DSB-repair activity of Nur77
ERK2 p38; MAPK1; MAPK2 Mediates transcriptional activation of Nur77 by Pin1
ERK5 ERK4; BMK1; MAPK7 Increases transcriptional activity of Nur77
JNK JNK1; MAPK8 Reduces DNA-binding ability, promotes nuclear export of
LKB1 hLKB1; STK11 No direct phosphorylation. LKB1 stays in the nucleus by b
thereby inhibiting AMPK signaling
PKA PKAC; PRKAC Decreases DNA-binding ability of Nur77, but increases DN
of Nur77 homodimers
PKC PRKC Induces mitochondrial translocation of Nur77. Inhibition
RSK1/2 S6K; p90-RSK;
RPS6KA1/3
Mitochondrial translocation of Nur77 and apoptosis in T c
Phosphorylation sites are given for human NR4A1, isoform 1 (GI:21361342); n.d., not determiaccessibility of only a single region of it. These conformational changes
can in turn lead to an increase or decrease in the protein's activity, sta-
bility or ability to interactwith other proteins. A number of kinases have
been shown to phosphorylate or interact with Nur77 directly, and these
interactions and modiﬁcations occur in all three of the domains of
Nur77 (Table 3).
4.1. Phosphorylation inhibits proteasomal degradation of Nur77
The peptidyl-prolyl isomerase Pin1 plays a role in post-translational
regulation of protein function by recognizing phosphorylated serine or
threonine residues and isomerizing the adjacent proline residues (so
called pSer/pThr-Promotifs). Pin1 interacts with all three NR4A nuclear
receptors and enhances their transcriptional activity [63,64]. However,
the exact regions of Nur77 that Pin1 binds or isomerizes are subjects
of debate as Nur77 contains 17 putative pSer/pThr-Pro motifs for isom-
erization by Pin1 and two papers have identiﬁed different motifs as
being essential for Pin1–Nur77 interactions. The ﬁrst paper, by Chen
et al., reported that Pin1 recognizes both JNK1-phosphorylated Ser95
and ERK2-phosphorylated Ser431 and subsequently isomerizes their
adjacent proline residues, which ultimately leads to increased protein
stability and transcriptional activity of Nur77, respectively [63,65]. In
contrast, van Tiel et al. reported that Pin1 enhancesNur77 transcription-
al activity independent of its isomerase activity and that the isomerase
activity of Pin1 is only required to increase the protein stability of
Nur77. Additionally, van Tiel et al. reported that phosphorylation of
Nur77 at the N-terminal domain Ser152 residue by casein kinase 2
(CK2) is required for isomerization to take place, which then leads to in-
creased protein stability by blocking ubiquitination of Nur77 [64]. Both
studies used Pin1 and Nur77 mutants to verify binding and isomeriza-
tion sites and all experiments were performed in HEK293 cells. So far
there is no explanation for the discrepancies between these two papers.
4.2. Phosphorylation by DNA-PK promotes the p53 transactivation and
DNA double-strand break repair activity of Nur77
DNA-PK is a serine/threonine protein kinase complex that is
expressed in the nucleus, where it plays an essential role in the non-
homologous end joining (NHEJ) pathway of DNA double-strand break
(DSB) repair [66]. DNA-PK has been shown to phosphorylate Nur77 at
two different sites with distinct downstream effects: ﬁrst, phosphoryla-
tion of Nur77 at the Ser164 residue promotes the Nur77-mediated inter-
action betweenDNA-PK and p53, resulting in phosphorylation of p53 and
subsequent enhancement of its transcriptional activity [67].Second,
Nur77 can also be phosphorylated by DNA-PK at residue Ser337 in re-
sponse to DNA damage, and this phosphorylation is crucial for the proper
progression of DSB repair [68]. However, the enhancement of DSB repair
does not depend on the transcriptional activity of Nur77, excluding thePhosphorylation site Interaction site References
f Nur77 Ser351 DBD [71,75]
Thr88 N-term [84]
Ser152 N-term [64]
Ser164 Ser337 N-term DBD [67,68]
Thr143 Ser431 N-term DBD [63,76,81,82]
n.d. (not Thr143) n.d. [83]
Nur77 Ser95 N-term [63,65,71,77]
inding Nur77, n.d. LBD [87]
A-binding ability Ser341 Ser351 DBD [44,74]
of the catalytic activity of PKCΘ Ser351 n.d. DBD [74,79,80]
ells Ser351 DBD [73,77,78]
ned.
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pair. Additionally, phosphorylation by DNA-PK is not required for recruit-
ment of Nur77 to sites of DNA repair, as DNA-PK only phosphorylates
Nur77 after it is already localized to DNA repair sites. Instead, the enzy-
matic activity of poly-ADP-ribose polymerase-1 (PARP-1) was shown to
be essential for recruitment of Nur77 to DNA repair sites [68]. Increased
DSB repair by Nur77 may therefore be seen as a two-step process: ﬁrst,
ribosylation by PARP-1 of either Nur77 itself (unconﬁrmed, but direct in-
teractions between PARP-1 and Nur77 do occur [69]) or the chromatin
surrounding the DSB (as has been previously shown to occur [70])
paves the way for a stable association of Nur77s with DSBs. Such an asso-
ciation then allows for recruitment of DNA-PK, which phosphorylates
Nur77 and thereby paves the way for recruitment of additional DNA re-
pair factors.
4.3. Subcellular localization of Nur77 is regulated by competing kinase
signaling pathways
Two major signaling pathways play an important role in mediating
the intracellular relay of cell proliferation and apoptosis signals: the
phosphatidylinositol 3-kinase to Akt/protein kinase B (PI3K-Akt) path-
way and the Ras to mitogen-activated protein kinase (MAPK) pathway.
These two pathways competitively alter the subcellular localization of
Nur77, with PI3K-Akt signaling promoting nuclear sequestration and
transcriptional inactivation ofNur77, andRas-MAPK signaling enhancing
mitochondrial translocation and transcriptional activation of Nur77
(Fig. 3). As described earlier in this review, translocation of Nur77 to
the mitochondria is a potent inducer of apoptosis. Therefore, the choice
in subcellular localization of Nur77 as decided by these two signaling
pathways can also be seen as a choice for either apoptosis or survival of
the cell. The effects of the PI3K-Akt signaling pathway on Nur77 are a
direct result of phosphorylation of Nur77 by Akt at residue Ser351. Phos-
phorylation of this residue, which is located in the DBD, has two effects
on Nur77: ﬁrst, it blocks export of Nur77 from the nucleus, presumably
through phosphorylation-dependent interactions between Nur77 and
the14-3-3 family of inactivating proteins (which have been shown to in-
teract with Nur77, albeit in vitro only) [71–73]. Second, phosphorylation
of Ser351 inhibits the ability of Nur77 to bindDNAand thereby decreases
its transcriptional activity [74,75].
On the other hand, activation of theMAPK pathwayhas less straight-
forward effects on Nur77, as it can induce both nuclear sequestration
and non-apoptotic cell death through ERK2 [76], as well as mitochon-
drial translocation and apoptosis through RSK/JNK [65,71,73,77,78].
More speciﬁcally, 90-kDa ribosomal S6 kinase (RSK2; also known as
p90-RSK) can phosphorylate the same Ser351 residue in the DBD of
Nur77 that was previously shown to be phosphorylated by Akt [73,77,
78]. Since phosphorylation of Ser351 can have seemingly opposite
effects depending on the kinase involved, it seems logical that a third
factor determines the ﬁnal effect phosphorylation of this residue has
on localization of Nur77. This third factor could be phosphorylation by
JNK, as it was shown that when the Ser95 residue in the N-terminal do-
main of Nur77 is phosphorylated by JNK, nuclear export and transloca-
tion of Nur77 to themitochondria is increased and Bcl-2mediated T-cell
apoptosis is promoted [65,71]. Another possibility is involvement of
protein kinase C (PKC), which also induces mitochondrial translocation
and is known to phosphorylate Nur77 in vitro [74,79]. Whether the
kinases described above synergistically promote translocation of
Nur77, or whether phosphorylation of Nur77 by these two kinases
only occurs separately from each other depending on cell type remains
to be determined. It should also be noted that in addition to the phos-
phorylation by PKC described above, interaction between the LBD of
Nur77 and a highly conserved glycine-rich loop of PKC was also
shown to inhibit its kinase activity [80].
ERK2 can phosphorylate Nur77 at residue Thr143, which also
sequesters Nur77 in the nucleus and thereby induces an alternative,
non-apoptotic form of programmed cell death that requirestranscriptional activation of Nur77 [76,81,82]. Additionally, ERK5 phos-
phorylates Nur77 as well (albeit at a different site than ERK2) and this
phosphorylation was shown to also increase apoptosis through induc-
tion of its transcriptional activity [83]. The idea of transcription-
dependent induction of cell death by Nur77 is made more plausible by
the fact that phosphorylation of residue Thr88 in Nur77 by checkpoint
kinase 2 (CHEK2) has already been described to have a similar
cell death-inducing effect by enhancing Nur77-dependent down-
regulation of expression of the anti-apoptotic genes BRE and RNF-7
[84]. In summary, phosphorylation by Akt inactivates and sequesters
Nur77 in the nucleus and thereby inhibits apoptosis, whereas the
MAPK pathway and/or PKC (possibly depending on the cell type)
can either enhancemitochondrial translocation of Nur77 and apoptosis
through JNK and RSK, or sequester Nur77 in the nucleus and thereby
promote non-apoptotic programmed cell death through ERK2.
Finally, it should be noted that the Ser351 residue of Nur77, whose
phosphorylation by kinases of the MAPK pathway and Akt was
discussed in the preceding paragraphs, is also phosphorylated by PKA
[74]. The exact effect of this phosphorylation by PKA is unclear however,
as activation of PKA has been shown to both increase and decrease tran-
scriptional activity of Nur77 [44,74].
4.4. Nur77 indirectly regulates AMPK activity through interactions with
LKB1
During times of energy starvation cellular levels of adenosine
monophosphate (AMP) rise and the appropriately named AMP-
activated protein kinase (AMPK) becomes activated through phosphor-
ylation by liver kinase B1 (LKB1). Activated AMPK is a major driver of
energy conservation in the cell, because it turns on energy producing
catabolic pathways such as fatty acid oxidation and glycolysis while
simultaneously shutting down energy-requiring processes such as
fatty acid synthesis, gluconeogenesis and cell growth [85]. Nur77 has
been shown to have the opposite effect of AMPK: it promotes gluconeo-
genesis, glucose metabolism and sensitivity to insulin [86]. This compe-
tition for themetabolic state of the cell between AMPK andNur77 is not
just indirect however, as Nur77 can also inhibit the activity of AMPK
through modulating the localization of LKB1. Nur77 directly interacts
with nuclear LKB1 and this interaction prevents LKB1 from leaving the
nucleus and activating cytosolic AMPK [87]. In the regulation of nuclear
export of LKB1 phosphorylation at its Ser428 residue is most important,
which is a target site for protein kinase C zeta (PKCζ) [88]. The LBD of
Nur77 and the region surrounding the PKCζ target residue Ser428 of
LKB1 interact with each other. This interaction prevents phosphoryla-
tion of LKB1 and thus its nuclear export [87].
5. Interacting proteins of Nurr1 and NOR-1
The interactome of Nurr1 is not as well described as that of Nur77,
whereas for NOR-1 even less data are available on its interacting
proteins. The reason why Nurr1 has been studied more elaborately
thanNOR-1may be its crucial function in development of dopaminergic
neurons as is illustrated by the brain phenotype of Nurr1-deﬁcientmice
[89]. In this paragraphNurr1-interactingproteinswill be presentedﬁrst,
followed by a description of our current knowledge on the protein–
protein interactions of NOR-1 (Tables 4–5).
5.1. The interactome of Nurr1
Nurr1 is both in its monomeric and homodimeric form an active
transcription factor, but it can also form heterodimers with Nur77 or
RXR. Nurr1 interactionwith RXRhas beendescribed in great detail dem-
onstrating that alanine substitution of Pro560 or Leu562 completely
disrupts this interaction, as well as the triple substitution of Lys554–
Leu555–Leu556 [90]. RXR is an inactive receptor in other nuclear recep-
tor dimeric complexes however, it creates a hormone-dependent
Table 4
Nurr1 interacting proteins.
Name Also known as Effect on Nurr1 activity Interacting domain of Nurr1 References
CTNNB1 ß-Catenin; armadillo Increased LBD [96]
CDKN1C Cyclin-dependent kinase inhibitor 1C; p57Kip2 Decreased N-term [94]
COPS5 COP9 signalosome subunit 5; Jab1 nd [102]
coREST REST corepressor 1; RCOR1 nd DBD [98]
ERK2 p38; MAPK1; MAPK2 Increased N-term [92,93]
ERK5 MAPK7 Increased N-term-LBD [92]
FHL2 Four and a half LIM domain 2; DRAL; SLIM3 Decreased LBD–DBD [59]
GR Glucocorticoid receptor; NR3C1 Increased DBD or N-term [10,91]
LEF1 Lymphoid enhancer-binding factor 1 nd LBD [96]
LIMK1 LIM kinase 1 Decreased N-term-LBD [92]
NCOR1 Nuclear receptor corepressor 1 nd [103]
NCOR2 Nuclear receptor corepressor 2; SMRT Decreased LBD [95,103]
NFKB NFKB-p65; NF-κB nd [98]
NR4A1 Nur77; NAK1; TR3; NGFI-B nd LBD
PIAS4 Protein inhibitor of activated STAT protein 4; PIASgamma Decreased N-term [100]
Pin1 Peptidyl-prolyl isomerase 1; DOD; UBL5 Increased [64]
PRKDC DNA-PKcs; DNA-PK nd DBD [68]
RSK1/2 S6K; p90-RSK; RPS6KA1/3 nd DBD [73]
RUNX1 AML1; CBFA2; EVI-1; PEBP2aB nd [97]
RXRA NR2B1 nd LBD [16,90,102]
SFPQ PSF; POMP100 nd [95]
SIN3A SIN3 transcription regulator family member A nd [95]
TP53 p53; TRP53 nd DBD [101]
TRIM28 TIF1β; KAP; TIF1B1 Increased [48]
FXR, PPAR, STAT3, PARP-1, p85 βPIX, MxiI nd [92]
N-term, indicates N-terminal domain; n.d., not determined.
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tional activity of Nurr1 itself is reduced upon complex formation with
RXR [16]. Nurr1 also interacts with the glucocorticoid receptor (GR) al-
though some discrepancy exists in literature on the domain of Nurr1
involved in this reaction, which has been described to be the DBD or
the N-terminal domain [10,91]. Nurr1 inhibits the transcriptional
activity of GR in AtT20 cells, whereas GR enhances Nurr1 activity in a
dexamethasone-dependent manner in PC12 cells [10,91].
In search for proteins that interact with Nurr1 extensive pull-
down experiments were performed, which revealed that the MAP
kinases ERK2 and ERK5 both bind to Nurr1 and enhance its transcrip-
tional activity in a phosphorylation-dependent manner [92]. For
ERK5 it was demonstrated that the Nurr1 Thr168A- and Ser177Ala-
variants were no longer responsive to ERK5 activation, whereas the
exact phosphorylation sites in Nurr1 for ERK2 were later identiﬁed
as Ser126 and Thr132 [93]. ERK2 interacts with the N-terminal
domain of Nurr1, whereas ERK5 was shown to bind the N-terminal
domain, where the target residues (Thr168, Ser177) are localized,
and the LBD.
LIM kinase1 and cyclin-dependent kinase inhibitor 1C (CDKN1C or
p57Kip2) are known to interact and have independently been shown
to bind the N-terminal domain of Nurr1 to inhibit the activity of Nurr1
[92,94]. Therefore, it is conceivable that the p57kip2–LIM kinase1–
Nurr1 complex exists. Moreover, LIM-domain containing proteins are
known to recruit the Sin3A-histone deacetylase co-repressor complex
and Nurr1 interacts directly with Sin3A, making the existence of an
even larger protein complex feasible [95].
The peptidyl-prolyl isomerase Pin1 was identiﬁed in a yeast-two-
hybrid screen and shown to interact with the N-terminal domain and
DBD of Nurr1. Pin1 enhances the transcriptional activity of Nurr1 with-
out changing its protein stability, in contrast to Nur77 protein stability
that is increased by Pin1 [63,64]. In the same screen the LIM-only do-
main protein FHL2 was identiﬁed and, similarly as observed for Nur77,
FHL2 binds theN-terminal domain and DBD of Nurr1 and inhibits its ac-
tivity [59, unpublished data van Tiel et al.].
As indicated above, Nurr1 is crucial in development of dopaminergic
neurons. In these cells Nurr1 is bound in corepressor complexes via
lymphoid enhancer-binding factor-1 (LEF-1). β-catenin competes for
this speciﬁc interaction with the Nurr1 LBD and upon binding toNurr1 β-catenin facilitates downstream gene expression of both Nurr1
and Wnt [96].
More recently, Nurr1 has been demonstrated to be involved in
expression of the Forkhead transcription factor Foxp3, which deﬁnes
the differentiation of regulatory T cells (Treg) [97]. This regulation
of gene expression in CD4+ T cells is mediated through direct inter-
action of Nurr1 with Runx1. In macrophages and microglia an anti-
inﬂammatory function has been attributed to Nurr1 involving inhibi-
tion of NF-κB p65 activity [98]. Indeed, a direct interaction between
Nurr1 and NF-κB p65 has been established, which requires phosphory-
lation of p65 at Ser468. Subsequently, the corepressor complex with
CoRest is recruited and this factor also binds Nurr1 directly. It is the
Nurr1/CoREST-mediated transrepression complex that blocks NF-κB
p65 activity.
In analogywith Nur77, Nurr1 is important in DNA repair through in-
teraction with DNA-PK, which phosphorylates Nurr1 at Ser337 in the
NR4A-conserved sequence ‘TDSLKG’. To substantiate its involvement
in dsDNA repair, overexpression of the Ser337Ala Nurr1-variant was
shown to hamper DNA repair [68].
The SUMO-E3 ligase PIASγ represses Nurr1 transcriptional activity
in two independent ways. One mechanism involves PIASγ-mediated
SUMOylation of Lys91 in Nurr1 resulting in reduced activity in complex
promoters. The other type of repression is mediated through a direct
interaction betweenNurr1 and PIASγ independent of its E3-ligase activ-
ity [99,100].
Proteins directly interacting with Nurr1, but for which the effect on
Nurr1 function has not been studied in detail are the nuclear receptors
FXR and PPAR, the transcription factors STAT3 and p53, PARP-1, which
is involved in apoptosis, p85 βPIX, a guanine nucleotide exchange factor
and JAB1, a component of the COP9 signalosome that acts as a positive
regulator of E3 ubiquitin ligases [92,101].
JAB1 is involved in the degradation of cyclin-dependent kinase
inhibitor CDKN1B/p27Kip1, but its effect on Nurr1 activity or protein
stability has not been studied [69,92,102].
Among the less well-deﬁned Nurr1 interacting proteins are also the
signaling pathway constituentsMxiI and NCoR-1 [92]. For NCoR-1 it has
been shown that a peptide comprising its LxxLLmotif interacts with the
novel co-regulator interaction site that has been deﬁned in the Nurr1
LBD domain, based on the LBD crystal structure and NMR-analyses
Table 5
NOR-1 interacting proteins.
Name Also known as Effect on NOR-1 activity Interacting domain of NOR-1 References
BCL2 Bcl-2; PPP1R50 nd [79]
CBP/p300 CBP; CREBBP; p300; EP300 nd [46]
ERK2 p38; MAPK1; MAPK2 nd [82]
FHL2 DRAL; FHL-2; SLIM3 Decreased [59]
TRAP220 MED1; RSP1; DRIP205; PBP; PPARBP; RB18A; TRIP2 Increased [104]
NCOA2 SRC-2; TIF2; GRIP1; NCoA-2 Increased N-term [104]
Pin1 Peptidyl-prolyl isomerase 1; DOD; UBL5 Increased N-term [64]
PARP1 poly-ADP-ribose polymerase-1 Decreased [69]
PKC PRKC nd [79]
PRKDC DNA-PKcs; DNA-PK nd DBD [68]
RSK1/2 S6K; p90-RSK; RPS6KA1/3 nd DBD [73]
SIX3 HPE2 Decreased DBD [108]
TRIM28 TIF1-β; KAP; TIF1B1 Increased DBD and LBD/DBD [48]
N-term, indicates N-terminal domain; n.d., not determined.
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known as SMRT) interacts with this novel co-regulator interaction site
in the LBD. Pitx3 disturbs the interaction between Nurr1 and NCoR-2/
SMRT and even though Nurr1 does not bind directly to Pitx3, these pro-
teins both bind the corepressor PSF indicating that Pitx3 and Nurr1 are
present in the same complex [95].5.2. The interactome of NOR-1
NOR-1 is less well studied than Nur77 and Nurr1 and most of the
data on interacting proteins of NOR-1 are presented in studies that are
mainly focused on its homologues. As a consequence, NOR-1 protein–
protein interactions are described with limited detail, for example the
HAT p300/CBP acetylates NOR-1 similarly as Nur77, however, the effect
on NOR-1 activity has not been described [79]. Likewise, NOR-1 inter-
acts with the co-regulator TIF1β resulting in enhanced NOR-1 activity,
but the domain involved in the interaction is unknown [48]. Similar to
Nur77, PKC and RSK1/2 were shown to induce NOR-1 mitochondrial
translocation [73,79] andDNA-PK binds the DBD of NOR-1. Even though
Nurr1 and Nur77 are both essential for optimal DSB repair the function
of NOR-1 in this process remains to be studied [68]. Both FHL2 and the
peptidyl-prolyl isomerase Pin1 bind the N-terminal domain and DBDFig. 2.Nur77 and its interacting proteins. Schematic overviewof theprotein–protein inter-
actionswith Nur77 for which the domains of interaction have been elucidated. Details are
described in the text and in Tables 1–3, which also contain the full names of the indicated
proteins. N-term, N-terminal domain; DBD, DNA-binding domain; LBD, ligand-binding
domain.of NOR-1, resulting in reduced or enhanced transcriptional activity of
NOR-1, respectively [59,64].
Muscat and co-workers performed detailed studies to identify co-
regulators of NOR-1 andwere the ﬁrst to reveal the absence of a conven-
tional ligand-binding pocket in the LBD of NOR-1, through molecular
modeling and hydrophobicity analysis of the LBD [104]. Based on
these analyses, the relative importance of the N-terminal domain of
NOR-1 in regulation of the transcriptional activity of NOR-1 became
apparent and direct interaction of a number of crucial co-regulators to
this domain was shown; SRC-2 (GRIP-1), SRC-1, SRC-3, p300, DRIP250/
TRAP220 and PCAF [104]. The interaction between the N-terminal
domain of NOR-1 and TRAP220 is independent of PKA- and PKC phos-
phorylation sites in TRAP220. Most interestingly, the purine derivative
6-mercaptopurine,which enhances the activity of NR4Aswithout directly
binding these nuclear receptors promotes the interaction betweenNOR-1
and TRAP220 [105].
Both Nur77 and NOR-1 are involved in T-cell receptor mediated
apoptosis of developing T cells [106]. During activation of T cells the
expression of NOR-1 is induced and protein kinase C (PKC) becomes ac-
tive. NOR-1 is a PKC substrate that is phosphorylated and subsequently
translocates from the nucleus to themitochondria where it binds Bcl-2.
Most interestingly, as already indicated above the interaction between
NOR-1/Nur77 and Bcl-2 causes a conformational change in Bcl-2
allowing its BH3 domain to be exposed, resulting in the conversion of
Bcl-2 from an anti-apoptotic into a pro-apoptotic protein. For Nur77 it
is exactly known which amino acids are involved to provoke the func-
tional switch in Bcl-2, which is not the case for NOR-1 [57,79].
Initially, the homeobox domain containing protein Six3 was identi-
ﬁed in a yeast-two-hybrid study as a protein that interacts uniquely
with the DBD and LBD of NOR-1 without binding or inhibiting the activ-
ity of Nur77 or Nurr1. Of interest, NOR-1 and Six3 show overlap in
expression in the rat fetal forebrain on embryonic day 18 [107]. In a
later study this speciﬁcity of Six3 for NOR-1was not found, rather inter-
action with all three NR4As was observed [108]. NOR-1 is part of the
EWS/NOR-1 fusion protein that is expressed in human extraskeletal
myxoid chondrosarcoma tumors. Six3 enhances the activity of NOR-1
(andNur77 and Nurr1), whereas the activity of EWS/NOR-1 is inhibited
and the interaction only requires the DBD of NOR-1. The opposing data
in these two studies may be explained by the use of different cell types
for the activity assays, as well as the use of Gal4-fusion proteins in the
latter study.
PARP-1 speciﬁcally and effectively interacts with the DBD of NOR-1
independent of the enzymatic activity of PARP-1 [69]. Nurr1 interacts
with lower afﬁnity, whereas EWS/NOR-1 and Nur77 do not bind
PARP-1, unless the N-terminal domain of Nur77 is deleted. The latter
experiment nicely illustrates that the N-terminal domains of Nur77
and EWS/NOR-1 disturb PARP-1 interaction with the DBD. This may
be the underlying mechanism of differential function of NOR-1 and
the EWS/NOR-1 fusion protein. In line with the binding characteristics,
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dently of the ribose polymerase activity of PARP-1.
6. Discussion and concluding remarks
This review summarizes the currently available knowledge on the
protein–protein interactions of the NR4A nuclear receptor family and
their downstream effects. When looking at the information gathered
in this review three main observations can be made. First, there are a
large number of protein–protein interactions that regulate the activity
of Nur77 and there is a large variation in the effects of these interactions
on the ‘target’ protein, be it Nur77 or the interacting protein itself. These
effects include modulation of transcriptional activity, protein stability,
post-translational modiﬁcation and cellular localization: all processes
that are tightly regulated by ligand binding in other nuclear receptors.
In light of the many interactions it undergoes with other proteins,
Nur77 could also be considered to be amolecular ‘chameleon’: a protein
that selectively adopts the responsiveness of other proteins by directly
interacting with them. Secondly, the protein–protein interactions with
Nur77 described in this review have been studied in a wide range of
cell types, such as immune cells (T-cells, thymocytes, monocytes and
macrophages); somatic cells (neurons, smoothmuscle cells, endothelialFig. 4. Amino-acid sequence similarity between the N-terminal domains of the NR4A recepto
aligned and the extent of sequence similarity is indicated with colors; e.g. blue indicates the
CHEK2 target Thr88, the JNK1 target Ser95, the ERK2 target Thr143, the CK2 target Ser152, and
gets Ser126 and Thr132, and the ERK5 targets Thr168 and Ser177 are indicated with arrows.cells and hepatocytes) and cancer cells from diverse origins. We reason
that a stimulus- and cell type-speciﬁc expression pattern of interacting
proteins may be decisive in determining both the interactions of NR4As
with other proteins and their activity in general. Thewell-studied inter-
action between Nur77 and RXRα, which has unique outcomes depend-
ing on both the cell type studied and the stimulus used, is one such
interaction that is modulated by stimulus- or cell type-speciﬁc auxiliary
proteins.
Lastly, there is a large amount of overlap in interacting proteins be-
tween the three NR4A nuclear receptors. All three domains of the
NR4As are involved in interactions with other proteins (Tables 1–5,
Fig. 2), and we think that the unstructured N-terminal domains are of
special interest as they have the lowest overall amino acid similarity
(Fig. 1). Based on this dissimilarity, it could be hypothesized that the
N-terminal domain of each NR4A receptor interacts with a unique set
of proteins that speciﬁcally regulates each of their activities, if it were
not for the fact that this review has shown that the interacting partners
of the NR4As strongly overlap. However, a closer look at the N-terminal
domains of Nur77, Nurr1 andNOR-1 reveals small stretches of relatively
high similarity within the amino acid sequences (Fig. 4). The possible
importance of these small stretches of high similarity is most readily
apparent when looking at phosphorylation sites of the NR4As. Forrs. The amino-acid sequence of the N-terminal domains of Nur77, Nurr1 and NOR-1 was
regions where the sequence of the three NR4As is identical. In the Nur77 sequence, the
the DNA-PK target Ser164 are indicatedwith arrows. In the Nurr1 sequence, the ERK2 tar-
2553K. Kurakula et al. / Biochimica et Biophysica Acta 1843 (2014) 2543–2555example, ERK2 phosphorylates both Nur77 and Nurr1 at highly con-
served sites in their N-terminal domains (Thr143 of Nur77 [82];
Ser126 and Thr132 of Nurr1) [93]. Additionally, NOR-1 is phosphorylat-
ed by ERK2 in vitro [82], but the exact phosphorylation site is not
known. Based on our hypothesis, it might be located in the same con-
served stretch of the N-terminal domain that is targeted by ERK2 in
Nur77 and Nurr1. Similarly, PKC and RSK1/2 were both shown to
target all three NR4As in their highly conserved DBDs.
In contrast, some kinases phosphorylate amino-acid residues that
are not located in conserved stretches. In line with our hypothesis,
these kinases only affect one of the NR4As. For example: protein stabili-
zation of Nur77 by Pin1, which requires phosphorylation of the poorly
conserved residues Ser95 or Ser152 by JNK1 or CK2, respectively. Pin1
does not affect Nurr1 or NOR1 protein stability, which could be caused
by the lack of CK2 or JNK1 consensus sites in these two proteins.
Similarly, DNA-PK and CHEK2 have only been shown to phosphory-
late Nur77 so far, and these two kinases both target poorly conserved
amino acid residues (Ser164 and Thr88, respectively) as well. Finally,
two ERK5 phosphorylation sites in Nurr1 (Thr168 and Ser177) are local-
ized in a region of the N-terminal domain with low amino acid sequence
similarity between the three familymembers, suggesting that Nur77 and
NOR-1 are not phosphorylated by ERK5 in this amino-acid stretch.
In summary, this review shows that even though the NR4As have no
known ligands, they are still tightly regulated through a plethora of
protein–protein interactions. Our current knowledge on the NR4A
interactome ismost likely far from complete and the exact interplay be-
tween the interacting proteins and the regulation of such interactions
will provide deeper inside in NR4A receptor function.Funding
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